ARS Pharma has claimed FDA approval for its epinephrine nasal spray neffy, becoming the first ... associate director of the division of pulmonology, allergy and critical care at the FDA's Center ...

Satsuma, a unit of a Japanese drugmaker with U.S. headquarters in Durham, said its treatment, called Atzumi, received its new ...

The US Food and Drug Administration (FDA) has approved dihydroergotamine (DHE) nasal powder (Atzumi, Satsuma Pharmaceuticals Inc) for the acute treatment of migraine with or without aura in adults ...

ARS Pharmaceuticals has announced the availability of neffy (epinephrine nasal spray ... 15 and 30kg. Approved by the US Food and Drug Administration (FDA) in March 2025, the spray is now ...

The FDA approved dihydroergotamine ... DHE is a migraine-specific acute medication first approved in 1946. It comes in several forms, including nasal sprays, injection, intravenous infusion ...

(RTTNews) - Satsuma Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration has approved a 505(b)(2) New Drug Application (NDA) for Atzumi(dihydroergotamine (DHE)) nasal powder ...